Previous 10 | Next 10 |
2023-08-01 06:04:29 ET Esperion Therapeutics press release ( NASDAQ: ESPR ): Q2 GAAP EPS of -$0.46 beats by $0.15 . Revenue of $25.79M (+36.9% Y/Y) beats by $1.15M . Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million Q2 Retail Prescription Equi...
– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for Expanded Indications in the U.S. and Europe; Label Change...
2023-07-31 13:07:06 ET Esperion Therapeutics ( NASDAQ: ESPR ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, before market open. The consensus EPS Estimate is -$0.63 (+40.0% Y/Y) and the consensus Revenue Estimate is $24.64M (+30.8% Y/Y). Over the...
ANN ARBOR, Mich., July 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the BTIG Virtual Biotechnology Conference 2023. Ben Halladay, Chief Financial Officer, will participate in a fireside chat on Monday, August 7, 2023 at 9:00 AM ET. The Esperion managem...
ANN ARBOR, Mich., July 17, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results before the market opens on Tuesday, August 1, 2023. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financ...
2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...
ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2023, in Arlington, TX. Esperion Therapeutics At Esperion, we discover, develop, and c...
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the application...
– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary prevention population, including 27% reduction in all-cause mortality – – Bempedoic acid is the first LDL...
ANN ARBOR, Mich., June 15, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented results from an analysis comparing the cardiovascular risk reduction benefits of bempedoic acid treatment with statin therapy per unit decrease in LDL-C, as observed in the CLEAR Outcomes study, at the 202...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...